
Giacomo Deferrari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1774482/publications.pdf Version: 2024-02-01



GIACOMO DEEEDDADI

#	Article	IF	CITATIONS
1	The role of kidney dysfunction in COVID-19 and the influence of age. Scientific Reports, 2022, 12, .	3.3	8
2	Renal dysfunction in cardiovascular diseases and its consequences. Journal of Nephrology, 2021, 34, 137-153.	2.0	32
3	Volatile Anesthetics <i>versus</i> Propofol for Cardiac Surgery with Cardiopulmonary Bypass. Anesthesiology, 2020, 132, 1429-1446.	2.5	54
4	Remote ischaemic preconditioning for renal and cardiac protection in adult patients undergoing cardiac surgery with cardiopulmonary bypass: systematic review and meta-analysis of randomized controlled trials. Nephrology Dialysis Transplantation, 2018, 33, 813-824.	0.7	32
5	High performance of a risk calculator that includes renal function in predicting mortality of hypertensive patients in clinical application. Journal of Hypertension, 2014, 32, 1245-1254.	0.5	9
6	Left-Ventricular Hypertrophy and Renal Outcome in Hypertensive Patients In Primary-Care. American Journal of Hypertension, 2013, 26, 700-707.	2.0	13
7	Sex differences in hypertension-related renal and cardiovascular diseases in Italy. Journal of Hypertension, 2012, 30, 2378-2386.	0.5	36
8	Metabolic syndrome and chronic kidney disease in high-risk Italian hypertensive patients: the I-DEMAND study. Journal of Nephrology, 2012, 25, 63-74.	2.0	15
9	Chronic Kidney Disease in the Hypertensive Patient. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 31-36.	2.2	6
10	Combined use of urinary neutrophil gelatinase-associated lipocalin (uNGAL) and albumin as markers of early cardiac damage in primary hypertension. Clinica Chimica Acta, 2011, 412, 1951-1956.	1.1	10
11	CKD Awareness and Blood Pressure Control in the Primary Care Hypertensive Population. American Journal of Kidney Diseases, 2011, 57, 71-77.	1.9	58
12	Serum Uric Acid Levels Predict New-Onset Type 2 Diabetes in Hospitalized Patients With Primary Hypertension: The MAGIC Study. Diabetes Care, 2011, 34, 126-128.	8.6	65
13	Chronic kidney disease in hypertension under specialist care: the I-DEMAND study. Journal of Hypertension, 2010, 28, 156-162.	0.5	40
14	Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. Journal of Hypertension, 2010, 28, 251-258.	0.5	25
15	Combined effect of albuminuria and estimated glomerular filtration rate on cardiovascular events and all-cause mortality in uncomplicated hypertensive patients. Journal of Hypertension, 2010, 28, 848-855.	0.5	30
16	Microalbuminuria Is a Predictor of Chronic Renal Insufficiency in Patients without Diabetes and with Hypertension. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1099-1106.	4.5	50
17	Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective. Nephrology Dialysis Transplantation, 2009, 24, 1528-1533.	0.7	21
18	Coronary Flow Reserve Is Impaired in Hypertensive Patients With Subclinical Renal Damage. American Journal of Hypertension, 2009, 22, 191-196.	2.0	32

#	Article	IF	CITATIONS
19	Effect of the Monocyte Chemoattractant Protein-1/CC Chemokine Receptor 2 System on Nephrin Expression in Streptozotocin-Treated Mice and Human Cultured Podocytes. Diabetes, 2009, 58, 2109-2118.	0.6	110
20	Mechanisms of renal ammonia production and protein turnover. Metabolic Brain Disease, 2009, 24, 159-167.	2.9	11
21	Androgen-mediated apoptosis of kidney tubule cells: Role of c-Jun amino terminal kinase. Biochemical and Biophysical Research Communications, 2009, 387, 531-536.	2.1	40
22	Cardiovascular Risk in Hypertensive Patients with Renal Dysfunction. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 13-20.	2.2	1
23	Renal and cardiac abnormalities in primary hypertension. Journal of Hypertension, 2009, 27, 1064-1073.	0.5	22
24	Independent association of ECG abnormalities with microalbuminuria and renal damage in hypertensive patients without overt cardiovascular disease: data from Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. Journal of Hypertension, 2009, 27, 410-417.	0.5	28
25	Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy. American Journal of Physiology - Renal Physiology, 2008, 295, F1563-F1573.	2.7	219
26	Vascular Permeability, Blood Pressure, and Organ Damage in Primary Hypertension. Hypertension Research, 2008, 31, 873-879.	2.7	11
27	Global risk stratification in primary hypertension: the role of the kidney. Journal of Hypertension, 2008, 26, 427-432.	0.5	28
28	Response to â€~Renal microvascular and tubular injuries in type II diabetic nephropathy'. Kidney International, 2008, 74, 390-391.	5.2	1
29	Inappropriate left ventricular mass is associated with microalbuminuria independently of left ventricular hypertrophy in primary hypertension. Journal of Hypertension, 2008, 26, 345-350.	0.5	13
30	Cardionephrology, an emerging discipline: highlights of the Sixth Genoa Meeting on Hypertension, Diabetes and Renal Disease. Therapy: Open Access in Clinical Medicine, 2007, 4, 487-489.	0.2	0
31	C-reactive protein and target organ damage in untreated patients with primary hypertension. Journal of the American Society of Hypertension, 2007, 1, 407-413.	2.3	8
32	Mild Hyperuricemia and Subclinical Renal Damage in Untreated Primary Hypertension. American Journal of Hypertension, 2007, 20, 1276-1282.	2.0	46
33	Microalbuminuria and Cardiovascular Risk Assessment in Primary Hypertension: Should Threshold Levels Be Revised?. American Journal of Hypertension, 2006, 19, 728-734.	2.0	15
34	Microalbuminuria, Blood Pressure Load, and Systemic Vascular Permeability in Primary Hypertension. American Journal of Hypertension, 2006, 19, 1183-1189.	2.0	25
35	Predicting cardiovascular risk using creatinine clearance and an artificial neural network in primary hypertension. Journal of Hypertension, 2006, 24, 1281-1286.	0.5	4
36	Ambulatory arterial stiffness index and renal abnormalities in primary hypertension. Journal of Hypertension, 2006, 24, 2033-2038.	0.5	77

#	Article	IF	CITATIONS
37	Evaluation of Subclinical Organ Damage for Risk Assessment and Treatment in the Hypertensive Patient: Role of Microalbuminuria. Journal of the American Society of Nephrology: JASN, 2006, 17, S112-S114.	6.1	19
38	Metabolic Syndrome and Cardiovascular Risk in Primary Hypertension. Journal of the American Society of Nephrology: JASN, 2006, 17, S120-S122.	6.1	20
39	Increased Ambulatory Arterial Stiffness Index Is Associated With Target Organ Damage in Primary Hypertension. Hypertension, 2006, 48, 397-403.	2.7	135
40	Vitamin E-coated filter decreases levels of free 4-hydroxyl-2-nonenal during haemodialysis sessions. Free Radical Research, 2006, 40, 207-212.	3.3	10
41	Importance of Blood Pressure Control in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, S98-S103.	6.1	104
42	Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. American Journal of Kidney Diseases, 2005, 45, 281-287.	1.9	317
43	Impact of Target Organ Damage Assessment in the Evaluation of Global Risk in Patients with Essential Hypertension: Figure 1 Journal of the American Society of Nephrology: JASN, 2005, 16, S89-S91.	6.1	16
44	Serum Uric Acid and Target Organ Damage in Primary Hypertension. Hypertension, 2005, 45, 991-996.	2.7	145
45	Prevention and Treatment of Diabetic Nephropathy: The Program for Irbesartan Mortality and Morbidity Evaluation. Journal of the American Society of Nephrology: JASN, 2005, 16, S48-S52.	6.1	30
46	Role of Microalbuminuria in the Assessment of Cardiovascular Risk in Essential Hypertension. Journal of the American Society of Nephrology: JASN, 2005, 16, S39-S41.	6.1	19
47	Mild Renal Dysfunction and Renal Vascular Resistance in Primary Hypertension. American Journal of Hypertension, 2005, 18, 966-971.	2.0	56
48	Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical Implications and Limitations. Journal of the American Society of Nephrology: JASN, 2005, 16, 3027-3037.	6.1	341
49	Optimizing Therapy in the Diabetic Patient with Renal Disease: Antihypertensive Treatment. Journal of the American Society of Nephrology: JASN, 2004, 15, 6S-11.	6.1	21
50	Oxidative Stress Mediates Apoptotic Changes Induced by Hyperglycemia in Human Tubular Kidney Cells. Journal of the American Society of Nephrology: JASN, 2004, 15, 85S-87.	6.1	77
51	Kidney Protein Dynamics and Ammoniagenesis in Humans with Chronic Metabolic Acidosis. Journal of the American Society of Nephrology: JASN, 2004, 15, 1606-1615.	6.1	36
52	RACE―and TGF―β receptorâ€mediated signals converge on STAT5 and p21 waf to control cellâ€cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy. FASEB Journal, 2004, 18, 1249-1251.	0.5	52
53	Testosterone promotes apoptotic damage in human renal tubular cells. Kidney International, 2004, 65, 1252-1261.	5.2	104
54	Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney International, 2004, 66, S99-S101.	5.2	40

#	Article	IF	CITATIONS
55	Optimizing global risk evaluation in primary hypertension. Journal of Hypertension, 2004, 22, 907-913.	0.5	36
56	Treatment of diabetic nephropathy in its early stages. Diabetes/Metabolism Research and Reviews, 2003, 19, 101-114.	4.0	19
57	Nephrin Expression Is Reduced in Human Diabetic Nephropathy. Diabetes, 2003, 52, 1023-1030.	0.6	319
58	Mild Renal Dysfunction and Subclinical Cardiovascular Damage in Primary Hypertension. Hypertension, 2003, 42, 14-18.	2.7	69
59	Interorgan exchange of aminothiols in humans. American Journal of Physiology - Endocrinology and Metabolism, 2003, 284, E757-E763.	3.5	35
60	Microalbuminuria, Cardiovascular, and Renal Risk in Primary Hypertension. Journal of the American Society of Nephrology: JASN, 2002, 13, S169-S172.	6.1	62
61	Renal and Cardiovascular Protection in Type 2 Diabetes Mellitus. Journal of the American Society of Nephrology: JASN, 2002, 13, S224-S229.	6.1	47
62	Taurine Prevents Apoptosis Induced by High Ambient Glucose in Human Tubule Renal Cells. Journal of Investigative Medicine, 2002, 50, 443-451.	1.6	87
63	Microalbuminuria identifies overall cardiovascular risk in essential hypertension: an artificial neural network-based approach Journal of Hypertension, 2002, 20, 1315-1321.	0.5	61
64	Changes in Renal Resistive Index and Urinary Albumin Excretion in Hypertensive Patients under Long-Term Treatment with Lisinopril or Nifedipine GITS. Nephron, 2002, 90, 169-173.	1.8	63
65	Microalbuminuria and subclinical cerebrovascular damage in essential hypertension. Journal of Nephrology, 2002, 15, 519-24.	2.0	34
66	Apoptosis Induced by Serum Withdrawal in Human Mesangial Cells. Nephron Experimental Nephrology, 2001, 9, 366-371.	2.2	14
67	5,10-methylenetetrahydrofolate reductase polymorphism and early organ damage in primary hypertension. American Journal of Hypertension, 2001, 14, 371-376.	2.0	27
68	Pulse pressure (PP) and early signs of target organ damage (TOD) in essential hypertension (EH). American Journal of Hypertension, 2001, 14, A161.	2.0	0
69	Fibroblast Na+–Li+ countertransport rate is elevated in essential hypertension. Journal of Hypertension, 2001, 19, 1263-1269.	0.5	9
70	Acute Effects of Peritoneal Dialysis with Dialysates Containing Dextrose or Dextrose and Amino Acids on Muscle Protein Turnover in Patients with Chronic Renal Failure. Journal of the American Society of Nephrology: JASN, 2001, 12, 557-567.	6.1	42
71	Genetic polymorphism of the renin-angiotensin system and organ damage in essential hypertension. Kidney International, 2000, 57, 561-569.	5.2	62
72	TT virus infection in haemodialysis patients. Nephrology Dialysis Transplantation, 2000, 15, 1823-1826.	0.7	11

#	Article	IF	CITATIONS
73	Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. Journal of Hypertension, 1999, 17, 993-1000.	0.5	97
74	Inter-organ Leptin Exchange in Humans. Biochemical and Biophysical Research Communications, 1998, 247, 504-509.	2.1	39
75	Treatment of Diabetic Nephropathy in its Early Stages. , 1997, 13, 51-61.		17
76	Prevalence and Clinical Correlates of Microalbuminuria in Essential Hypertension. Hypertension, 1997, 30, 1135-1143.	2.7	165
77	Renal Metabolism of C-Peptide in Patients with Early Insulin-Dependent Diabetes mellitus. Nephron, 1996, 72, 395-401.	1.8	9
78	Medicine in Italy. Lancet, The, 1996, 348, 679.	13.7	1
79	Skeletal muscle protein synthesis and degradation in patients with chronic renal failure. Kidney International, 1994, 45, 1432-1439.	5.2	126
80	Muscle Amino Acid and Protein Metabolism in Chronic Renal Failure. Contributions To Nephrology, 1992, 98, 1-10.	1.1	4
81	Renal metabolism of amino acids in early insulin-dependent diabetes mellitus. The Journal of Diabetic Complications, 1991, 5, 101-103.	0.2	0
82	Renal ammoniagenesis in humans with chronic potassium depletion. Kidney International, 1991, 40, 772-778.	5.2	39
83	Abnormalities in Amino Acid Metabolism in Chronic Renal Failure. Contributions To Nephrology, 1990, 81, 169-180.	1.1	1
84	Amino Acid Imbalance in Patients with Chronic Renal Failure. Contributions To Nephrology, 1989, 75, 185-193.	1.1	10
85	Renal Metabolism of C-Peptide in Man*. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 494-498.	3.6	67
86	Abnormalities in Amino Acid Metabolism in Patients with Chronic Renal Failure. Contributions To Nephrology, 1987, 55, 1-10.	1.1	1
87	Leg Metabolism of Amino Acids and Ammonia in Patients with Chronic Renal Failure. Clinical Science, 1985, 69, 143-151.	4.3	36
88	Brain metabolism of amino acids and ammonia in patients with chronic renal insufficiency. Kidney International, 1981, 20, 505-510.	5.2	50